Atara Bio announces results from ongoing phase 2 trial of allogeneic CMV
Atara Biotherapeutics announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center reported Phase 2 results for the efficacy and safety of CMV-CTL in treatment of 15 patients with documented CMV mutations conferring resistance to anti-viral therapies. December 03, 2016